Epigenetic silencing of the 3p22 tumor suppressor \textit{DLEC1} by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas

Zhaohui Wang$^{1,2 \dagger}$, Lili Li$^{1,2 \dagger}$, Xianwei Su$^2$, Zifen Gao$^3$, Gopesh Srivastava$^4$, Paul G Murray$^5$, Richard Ambinder$^6$ and Qian Tao$^{1,2,6 \ast}$

Abstract

\textbf{Background:} Inactivation of tumor suppressor genes (TSGs) by promoter CpG methylation frequently occurs in tumorigenesis, even in the early stages, contributing to the initiation and progression of human cancers. \textit{Deleted in lung and esophageal cancer 1} (\textit{DLEC1}), located at the 3p22-21.3 TSG cluster, has been identified frequently silenced by promoter CpG methylation in multiple carcinomas, however, no study has been performed for lymphomas yet.

\textbf{Methods:} We examined the expression of \textit{DLEC1} by semi-quantitative reverse transcription (RT)-PCR, and evaluated the promoter methylation of \textit{DLEC1} by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) in common lymphoma cell lines and tumors.

\textbf{Results:} Here we report that \textit{DLEC1} is readily expressed in normal lymphoid tissues including lymph nodes and PBMCs, but reduced or silenced in 70\% (16/23) of non-Hodgkin and Hodgkin lymphoma cell lines, including 2/6 diffuse large B-cell (DLBCL), 1/2 peripheral T cell lymphomas, 5/5 Burkitt, 6/7 Hodgkin and 2/3 nasal killer (NK)/T-cell lymphoma cell lines. Promoter CpG methylation was frequently detected in 80\% (20/25) of lymphoma cell lines and correlated with \textit{DLEC1} downregulation/silencing. Pharmacologic demethylation reversed \textit{DLEC1} expression in lymphoma cell lines along with concomitant promoter demethylation. \textit{DLEC1} methylation was also frequently detected in 32 out of 58 (55\%) different types of lymphoma tissues, but not in normal lymph nodes. Furthermore, \textit{DLEC1} was specifically methylated in the sera of 3/13 (23\%) Hodgkin lymphoma patients.

\textbf{Conclusions:} Thus, methylation-mediated silencing of \textit{DLEC1} plays an important role in multiple lymphomagenesis, and may serve as a non-invasive tumor marker for lymphoma diagnosis.

\textbf{Keywords:} \textit{DLEC1}, CpG, Methylation, Tumor suppressor, Lymphoma

Introduction

Epigenetic silencing of tumor suppressor genes (TSGs) by promoter CpG methylation and histone modification has been widely recognized as one of the major causes of tumorigenesis including hematological malignancies [1,2]. Aberrant methylation of TSG is frequently detected even in the early stage of tumorigenesis, suggesting its potential as tumor biomarker for early detection and therapeutic targeting.

Deletions of the 3p22-21.3 region have been identified as one of the earliest molecular events in various malignancies [3], including nasopharyngeal [4], head and neck [5], lung [6], gastric [7], breast [8], cervix [9] and renal [10] carcinomas, as well as lymphomas [11]. A growing number of TSGs, including \textit{RASSF1A} [12,13], \textit{BLU/ZMYND10} [14,15], and \textit{CACNA2D2} [16], have been identified in this region [17,18]. Frequent inactivation of several 3p21.3 genes as functional TSGs, such as \textit{RASSF1} and \textit{BLU} [14,19], by promoter CpG methylation had been identified associated with tumor initiation and
progression. For example, promoter methylation of RASSF1A has been shown related to poor prognosis and advanced tumor stage of certain tumor types [20-33]. Restoration of RASSF1A in cancer cell lines inhibited tumor cell growth and metastasis [34]. Thus, 3p22-21.3 is a critical TSG cluster in tumorigenesis [3,18].

Deleted in lung and esophageal cancer 1 (DLEC1), a 3p22 cluster genes, was first identified as a TSG in esophageal and lung cancers [35]. Downregulation of DLEC1 by promoter methylation has been found in multiple cancers, including nasopharyngeal [36,37], ovarian [38], lung [39], hepatocellular [40], gastric [41], renal [42], and breast carcinomas [43], suggesting its potential as a broad TSG [44,45]. Remarkably, DLEC1 was methylated in breast cancer as well as pre-invasive lesions but rarely in normal breast tissues, indicating its potential as an epigenetic marker for early tumors [43].

In this study, we examined the expression and methylation status of DLEC1 in lymphoma cell lines and tissues, and evaluated its potential as a tumor marker for the early detection of hematologic tumors.

Methods

Cell lines and tumor samples

Non-Hodgkin and Hodgkin lymphoma cell lines studied included diffuse large B-cell lymphoma (DLBCL) cell lines (OCI-Ly1, Ly3, Ly7, Ly8, Ly18, SUDHL6); peripheral T cell lymphoma (PTCL) cell lines (Ly13.2, Ly17); Burkitt lymphoma (BL) cell lines (AG876, BJAB, Namalwa, Rael, Raji); Hodgkin lymphoma (HL) cell lines (L428, L540, L591, L1236, KM-H2, HD-LM-2, HD-MY-Z) (DSMZ cell collection, Braunschweig, Germany); and natural killer (NK)/T-cell lines (NL) (KHYG-1, SNK6, YT) [46-48]. Cell lines were maintained in RPMI1640 or Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal calf serum (FBS) (Invitrogen, Paisley, Scotland) and 1% streptomycin/penicillin at 37°C in 5% CO2. HL cell lines were treated with 5 μM of 5-aza-2’-deoxycytidine (Aza) (Sigma) for 3 days, or further treated with 100 nmol/L trichostatin A (Cayman Chemical Co., Ann Arbor, MI, USA) for additional ~16 h as described previously [15,49], and L428 and KM-H2 cell lines were treated with Aza for 6 days.

Normal peripheral blood mononuclear cells (PBMC), lymph node samples, different types of lymphoma samples, as well as sera from healthy individuals and HL patients were collected as previously described, and the reliability and quality of all the studied samples in this study have been confirmed before [41,47,50]. The study was approved by Johns Hopkins Medicine Institutional Review Board. Normal adult tissue RNA samples were purchased commercially (Stratagene, La Jolla, CA, USA or Millipore-Chemicon, Billerica, MA, USA). DNA and RNA were extracted from lymphoma cell lines and primary lymphomas using TRIzol reagent (Invitrogen) as previously described [51,52].

Semi-quantitative reverse transcription (RT)-PCR

RT-PCR was performed as previously described [40,41]. Primers used for RT-PCR are: DLEC1A: 5’-ttctccctgc cctac, DLEC1B: 5’-aaactcatccagccgctg; GAPDH33: 5’-gtagcctgccccacagcct, GAPDH55: 5’-atctctgccccctctgctga.

RT-PCR was done with 32 cycles for DLEC1 and 23 cycles for GAPDH.

Bisulfite treatment and promoter methylation analysis

Bisulfite modification of DNA, methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS) were...
performed as described [53,54]. MSP primers for DLEC1 were: DLEC1m1: 5'-gtttcgtagttcggtttcgtc; DLEC1m2: 5'-cgaatatctttaatacgcaacg; DLEC1u1: 5'-agtttlttagttgtttgt tgtt; DLEC1u2: 5'-acaataatctttaaatcagaca. For BGS, bisulfite-treated DNA was amplified using primers DLEC1BGS1: 5'-gaagatataaatgtttataatgatt; DLEC1BGS4: 5'-aactacaaccaccccaatctta. ANKRD30Am1: 5'-cggttaggtgtta ttgtacctg; ANKRD30Am2: 5'-tcctctctcaaatcctaa. MSP and BGS were performed for 40 cycles by using the AmpliTaq-Gold DNA polymerase (Applied Biosystems). All primer sets were previously tested for not amplifying any unbisulfited DNA. Amplified BGS products were

Figure 2 Promoter CpG methylation of DLEC1 in lymphoma cell lines. A. Diagram shows the DLEC1 CpG island, exon 1 (indicated with a rectangle), and CpG sites (short vertical lines). Numbers from 1 to 61 indicate the individual CpG sites. B. DLEC1 methylation as measured by MSP in lymphoma cell lines. M: methylated; U: unmethylated; DLBCL: diffuse large B-cell lymphoma; BL: Burkitt lymphoma; HL: Hodgkin lymphoma; NL: nasal NK/T-cell lymphoma. C. High resolution mapping of the methylation status of the DLEC1 promoter by BGS in normal PBMCs, and representative BL and HL cell lines. The DLEC1 transcription start site is shown as bent arrows. Circles, CpG sites analyzed; row of circles, an individual promoter allele that was cloned, randomly selected, and sequenced; filled circle, methylated CpG site; open circle, unmethylated CpG site.
DLEC1 was downregulated by promoter CpG methylation in lymphoma cell lines

We first examined the expression of DLEC1 mRNA in 25 non-Hodgkin and Hodgkin lymphoma cell lines by RT-PCR. DLEC1 was highly expressed in the normal lymph node, PBMC samples, as well as human adult testis and bone marrow tissues (Figure 1A), but silenced or reduced in 33% (2/6) DLBCL, 50% (1/2) PTCL, 100% (5/5) BL, 86% (6/7) HL, and 67% (2/3) NL cell lines (Figure 1B), indicating that DLEC1 is a candidate TSG for lymphomas.

The promoter and exon 1 region of DLEC1 is a typical CpG island, with a T/C SNP site at CpG#29 (Figure 2A). MSP analysis showed that DLEC1 promoter methylation was frequently detected in 3/6 DLBCL, 1/2 PTCL, 5/5 BL, 7/7 (one weak) HL, and 2/3 NL cell lines (Figure 2B; Table 1), well correlated with its silencing or reduction. DLEC1 methylation was further verified in detail by BGS analysis of 61 CpG sites within the CpG island. CpG sites of DLEC1 examined were heavily methylated in BL cell lines Rael, Raji, and in the HL cell line L428, but rarely in all normal PBMC samples, which confirmed the MSP data (Figure 2C). These results indicate that DLEC1 silencing by promoter methylation is a critical event in lymphomagenesis.

Silencing of DLEC1 could be reversed by pharmacologic demethylation

To further confirm whether promoter methylation mediates the loss of DLEC1 expression in lymphoma, lymphoma cell lines with methylated and reduced DLEC1 were treated with the DNA methylation inhibitor, Aza, alone or combined with the HDAC inhibitor trichostatin A (TSA). After Aza treatment, DLEC1 expression was significantly induced in cell lines Rael, L428, L1236 and KM-H2. MSP analysis showed increased unmethylated alleles. Similar results were obtained using a combination treatment of Aza and TSA (Figure 3). Demethylation of the DLEC1 promoter was further confirmed by BGS. These results confirmed that promoter CpG methylation directly mediates DLEC1 silencing in lymphomas.

DLEC1 is frequently methylated in primary lymphomas

We next investigated DLEC1 methylation in different types of primary lymphomas. Of 58 lymphoma tissues, DLEC1 methylation was detected in 5/6 (83%) BL, 16/30 (53%, one weak) HL, 1/10 (10%) DLBCL, 6/8 (75%) NL, and 4/4 (100%, two weak) follicular lymphoma (FL) tumor samples, while no methylation was detected in normal lymph node samples (Figure 4A and B; Table 1).

Table 1 Frequencies of DLEC1 methylation in various lymphoma tissues

| Lymphoma Type                        | DLEC1 promoter (methylated) |
|--------------------------------------|-----------------------------|
| Cell lines                           |                             |
| Diffuse large B-cell lymphoma        | 50% (3/6)                   |
| Peripheral T-cell lymphoma           | 50% (1/2)                   |
| Burkitt lymphoma                     | 100% (5/5)                  |
| Hodgkin lymphoma                     | 100% (7/7, one weak)        |
| Nasal NK/T-cell lymphoma             | 67% (2/3)                   |
| Tumors                               |                             |
| Burkitt lymphoma                     | 83% (5/6)                   |
| Diffuse large B-cell lymphoma        | 10% (1/10)                  |
| Nasal NK/T-cell lymphoma             | 75% (6/8)                   |
| Hodgkin lymphoma                     | 53% (16/30, one weak)       |
| Follicular lymphoma                  | 100% (4/4, two weak)        |
| HL sera                              | 23% (3/13)                  |
| Normal sera                          |                             |
| Normal lymph node                    | 0/9                         |
| Normal sera                          | 0/20                        |

Unmethylated bands were detected in all samples due to the inevitable inclusion of non-tumor cells in the analysis. Furthermore, the reduction or silencing of DLEC1 expression was observed in 6 out of 7 (86%) NL tumors as measured by RT-PCR.

Furthermore as a pilot study, we examined DLEC1 methylation in serum samples of 13 HL patients with sera from 20 healthy individuals as controls. ANKRD30A is a normally methylated gene, thus used as an internal control for validating genomic DNA integrity of these samples, in addition to unmethylated DLEC1. Results showed that DLEC1 methylation was detected in 3/13 (23%) sera from HL patients (Figure 4D) but not in any normal sera.

Discussion

DLEC1 is located in the commonly deleted region 3p22-21.3 [3,18]. A cluster of TSGs, including RASSF1A, BLU, and CACNA2D2, has been identified within this region. Silencing of RASSF1A, BLU, as well as DLEC1 by promoter CpG methylation had been extensively identified in multiple human cancers. Notably, promoter methylation of several 3p22-21.3 TSGs, such as RASSF1A and BLU, has also been identified in lymphomas [50,55], suggesting that TSGs in this region are frequently susceptible to epigenetic disruption during lymphoma pathogenesis.

Here, we report that DLEC1 is frequently silenced by promoter methylation both in lymphoma cell lines and primary lymphomas, but seldom in normal lymph nodes and PBMCs. Pharmacologic demethylation could reactivate DLEC1 expression, suggesting that epigenetic mechanism including DNA methylation and histone modification mediates DLEC1 transcriptional silencing. As primary tumor tissues usually contain infiltrating...
non-malignant cells such as lymphocytes, unmethylated alleles were detected in all the tumor samples which also acting as an internal control for genomic DNA integrity. 

*DLEC1* unmethylated alleles and *ANKRD30A* methylated alleles detected in different types of normal and lymphoma samples indicated the reliability of these samples as shown before. *DLEC1* methylation showed a relatively low frequency in DLBCL samples, compared to other lymphoma types. The reason for this difference is not clear probably due to the special biologic features of

---

**Figure 3** Pharmacologic demethylation restored *DLEC1* expression in methylated/silenced lymphoma cell lines. A. Expression and methylation analyses of *DLEC1* in HL cell lines with Aza treatment or combined with TSA (A+T). M: methylated; U: unmethylated. B. BGS analysis of *DLEC1* methylation in lymphoma cell line KM-H2 before and after 5 μM Aza treatment.

---

**Figure 4** *DLEC1* is frequently methylated in lymphoma tissues. A. MSP analysis of *DLEC1* methylation in normal lymph node samples. Templates used for positive controls are: bisulfite treated DNA from HCT116 (+ve-control1) and HT-29 (+ve-control2) cell lines for methylation; SW480 (+ve-control1) and SNU16 (+ve-control2) cell lines for unmethylation. B. Representative analyses of *DLEC1* methylation in primary lymphomas by MSP in primary lymphoma BL, DLBCL, HL and FL samples. BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; HL: Hodgkin lymphoma; NL: nasal NK/T-cell lymphoma; FL: follicular lymphoma. C. Representative analysis of *DLEC1* expression in NL tumors. GAPDH was used as an internal control. D. Representative MSP analysis of *DLEC1* methylation in serum samples from HL patients and normal controls. Positive controls: bisulfite treated DNA from HCT116 (+ve-control1) and HT-29 (+ve-control2) cell lines. M: methylated; NS: non-specific band.
DLBCL, which needs to be further confirmed by large sample size. Our results suggest that epigenetic silencing of DLEC1 is important for lymphoma pathogenesis. Remarkably, DLEC1 is specifically methylated in sera of HL patients, suggesting its potential as an epigenetic biomarker for the non-invasive diagnosis of lymphomas.

Conclusions
This study identifies the frequent epigenetic inactivation of DLEC1 in various lymphomas and demonstrates its potential as a non-invasive tumor marker for the detection of lymphomas. More molecular studies on the tumor suppressive functions of DLEC1 in lymphoma pathogenesis are needed.

Competing interests
The authors declare no conflict of interest.

Authors’ contributions
ZW and LL analyzed data and drafted the manuscript. XS and ZW acquired data. ZG, GS, PGM and AR provided material and reviewed the manuscript. PGM contributed to the writing of the manuscript. QT conceived and supervised the study, analyzed data and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgments
This study was supported by National Natural Science Foundation of China (#81071634 and 81172582), Shenzhen Science Fund for Distinguished Young Scholars (#JC201005270328A) the Leukaemia Lymphoma Research of Young Scholars (#JC201005270328A) the Leukaemia Lymphoma Research of Young Scholars (#JC201005270328A) the Leukaemia Lymphoma Research of Young Scholars (#JC201005270328A). We thank Dr. Ricardo Dalla-Favera for the DLBCL cell lines, Drs. Teresa Marafioti and (David Y Mason) for the L1236 cell line, Drs. Norio Shimizu for the L1236 cell line, Drs. Norio Shimizu for the L1236 cell line, Drs. Norio Shimizu for the L1236 cell line, Drs. Norio Shimizu for the L1236 cell line. The authors declare no conflict of interest.
27. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Cirt Cancer Res 2009, 3:9281–9284.

28. Wagner KL, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadley RB, Morton D, Schofield PN, Reik W, Latif F, Maher ER. Frequent RASSF1A tumor suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002, 21:7777–7782.

29. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002, 21:6839–6840.

30. Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, Weichertbaum R, Kuo MJ, Maher ER, Latif F. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumor suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002, 38:1585–1592.

31. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Latif F, Maher ER. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001, 98:7504–7509.

32. Lo KW, Kwong J, Lin A, Ambinder RF, Chong SY, To KF, Chan AS, Chow LS, Teo PA, Johnson PJ, Huang DP. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001, 61:3877–3881.

33. Barbee DG, Forcaga, Zechbauer-Moller, S, Shikavukia L, Fong K, Gao B, Randle D, Kondor M, Virmanni A, Bader S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001, 93:691–699.

34. Chow LS, Lam CW, Chan SY, Tsao SW, To KF, Tsang SH, Hung WK, Dammann R, Huang DP, Lo KW. Identification of RASSF1A methylated genes in nasopharyngeal carcinoma. Oncogene 2006, 25:310–316.

35. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y. Molecular cloning of a candidate tumor suppressor gene, DLEC1, from chromosome 3p21.3. Cancer Res 2009, 59:1966–1972.

36. Kwong J, Chow LS, Wong AY, Hung WK, Chung GT, To KF, Chan FL, Daigo Y, Nakamura Y, Huang DP, Lo KW. Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer 2007, 46:171–180.

37. Ayadi W, Karrak-Hakim H, Kabir A, Feki L, Chafi S, Boudawara T, Ghobrial A, Daoud J, Frihka M, Busson P, Hammani A. Averrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res 2008, 28:2161–2167.

38. Kwong J, Lee JY, Wong HK, Zhou X, Wong DT, Lo KW, Welch WP, Berkwitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 2006, 8:266–278.

39. Seng TJ, Cuney C, Cooper WA, Lee CS, Chan C, Honath P, Sutherland RL, Kennedy C, McCaughan B, Kohonen-Corish MR. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 2008, 99:375–382.

40. Qiu GH, Salto-Tellez M, Ross JA, Yeo W, Cui Y, Wheelhouse N, Chen GG, Hsu C, Gao Z, Wei W, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004, 23:1326–1331.

41. Cheng Y, Geng H, Cheng SH, Li X, Li J, Srivastava G, Ng MH, Fukagawa T, Wu X, et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple cancers. Cancer Res 2010, 70:6516–6526.

42. Jin H, Wang X, Ying J, Wang AH, Cui Y, Srivastava G, Shen ZY, Li EM, Zhang Q, Jin J, et al. Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL1 defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci USA 2007, 104:12353–12358.

43. Tao Q, Robertson KD, Manns A, Hildeashein A, Ambinder RF. The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 1998, 72:7075–7083.

44. Tao Q, Swimmenn LI, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 1999, 155:619–625.

45. Toujani S, Dessen P, Ithzar N, Donqlot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, Da Costa L, et al. High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PLoS One 2009, 4:e7089.